Clinical trials: Rubella, open to volunteers
Measles, Rubella
Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months
This study will be conducted among 1530 healthy infants of 9 to 12 months of age residing in the Dakshinkhan and Uttarkhan area which is located in Dhaka North City Corporation (DNCC) to enroll the required number of…
- Conditions
- Measles, Rubella, Yellow Fever
- Trial name
- NCT06815835
- Testing
- Measles-Rubella vaccine (Live) I.P. (Freeze Dried) of M/s. Zydus Lifesciences Ltd, Yellow fever Vaccine (WHO prequalified)
- Where
- Bangladesh
- Volunteers
- 1,530 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Measles, Measles-Mumps-Rubella+Chickenpox Vaccine
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella)…
- Trial name
- NCT07406360
- Testing
- MMRVNS, MMRV
- Where
- 17 sites in United States
- Volunteers
- 1,209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chickenpox
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection.
- Trial name
- NCT06855160
- Testing
- Candidate varicella vaccine, Marketed varicella vaccine, MMR vaccine
- Where
- 22 sites in United States, Belgium and 5 more
- Volunteers
- 911 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Exanthema, Dengue Fever
Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections
Exanthematous fevers are a global public health problem. The spread of arboviruses due to various factors, including climate change, has resulted in major epidemics such as the one that occurred in Brazil in 2024, representing an…
- Conditions
- Exanthema, Dengue Fever, Chikungunya, Measles
- Trial name
- CRIUS (NCT07112846)
- Volunteers
- 830 people
- Sponsor
- Hospital Israelita Albert Einstein
Polio, Measles
the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
This study evaluated the antibody persistence of Chinese children five years after they received four doses of sIPV, two doses of MMR vaccine and one dose of HepA-L vaccine.
- Conditions
- Polio, Measles, Rubella, Mumps
- Trial name
- NCT07338851
- Where
- 6 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Measles, Mumps
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age
The purpose of this study is to evaluate how consistently 3 different manufacturing lots of the GSK's investigational measles, mumps, rubella, and varicella (MMRVNS) vaccine will produce an immune response.
- Conditions
- Measles, Mumps, Rubella, Varicella (Chickenpox)
- Trial name
- MMRVNS 20-002 (NCT07742644)
- Testing
- MMRVNS vaccine, MMRV vaccine, DTaP-IPV vaccine
- Where
- 62 sites in United States, Argentina and 4 more
- Volunteers
- 1,860 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Polio, Diphteria, Tetanus and Pertussis
Study of Concomitant Administration of the sIPV and DTaP or MMR
This study is a randomized, open-labeled phase IV clinical trial to evaluate the immunogenicity and safety of concomitant administration of sIPV and DTaP or MMR in infants aged 2 months.
- Conditions
- Polio, Diphteria, Tetanus and Pertussis, MMR Vaccine
- Trial name
- NCT06920069
- Testing
- sIPV, DTaP, bOPV 1,3
- Where
- 9 sites in China
- Volunteers
- 2,640 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
Respiratory Tract Infections, Infections
Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children
The goal of this clinical trial is to evaluate the off-target/non-specific effects of the measles-mumps-rubella (MMR) vaccine in children.
- Conditions
- Respiratory Tract Infections, Infections, Allergy, Eczema
- Trial name
- NEMAU (NCT05758532)
- Testing
- Measles-Mumps-Rubella vaccine (MMR)
- Where
- Switzerland
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Laure Pittet, MD-PhD
Vaccination Failure, Vaccine Response Impaired
Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
The current recommendation for a full course of measles-mumps-rubella-(varicella) vaccine (MMR(V)) is two doses. The problem is, many individuals within the vaccinated cohort show antibody levels that are below the level…
- Trial name
- NCT05923970
- Testing
- Serology for antibody levels - Baseline, Serology to assess cell mediated immune (CMI) response - Baseline, Serology for antibody levels - Post third dose of MMR vaccine
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- University of Alberta
Heart Transplant Infection Prevention
Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients
The study is an interventional, non-randomized assessment of safety and efficacy of live Measles, Mumps and Rubella (MMR) vaccine in subjects aged 12-months to 17 years who have undergone heart transplantation.
- Trial name
- NCT07195032
- Testing
- Commercial measles, mumps, and rubella (MMR) vaccine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Children's Mercy Hospital Kansas City
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge